ABSCIENCES (EPA:AB) AB SCIENCE - Half-year report on liquidity contract
Transparency directive : regulatory news
09/07/2010 17:45
Click here to download pdf version
Paris, July 9th, 2010 - 5.45 pm
Half-year report on AB Science's liquidity contract
Under the liquidity contract entrusted by AB Science to SG Securities (Paris),
the following assets appeared on the liquidity account at 30 June 2010:
- 150 shares
- EUR98.267,50
For information, the following assets appeared on the liquidity account at 23
June 2010:
- 0 share
- EUR100.000,00
About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of pro tein kinase inhibitors
(PKIs), a new class of targeted molecules whose action is to modify signalling
pathways within cells. Through these PKIs, the Company targets diseases with
high unmet medical needs (cancer, inflammatory diseases and central nervous
system diseases), in both human and veterinary medicines. Thanks to its
extensive research and development capabilities, AB Science has its own
portfolio of molecules. Masitinib, a lead compound, has already been registered
in veterinary medicine in Europe and is pursuing three on-going phases 3 in
human medicine in pancreatic cancer, GIST and mastocytosis.
AB Science is listed on NYSE Euronext Paris (Compartment B) - ISIN:
FR0010557264 - Ticker: AB
Further information is available on AB Science's website:
www.ab-science.com
Financial Communication & Press Relations
Contacts Citigate Dewe Rogerson :
Agnès Villeret - Tel: +33 1 53 32 78 95 - agnes.villeret@citigate.fr